NasdaqGS:TYRABiotechs
Is Tyra Biosciences’ (TYRA) ASCO GU Spotlight Quietly Reframing Its Bladder Cancer Pipeline Narrative?
Tyra Biosciences recently announced that two clinical abstracts on its precision FGFR3 inhibitor TYRA-300 in metastatic urothelial cancer and non-muscle invasive bladder cancer were accepted for presentation at the 2026 ASCO Genitourinary Cancers Symposium.
This acceptance highlights growing clinical and scientific interest in TYRA-300’s potential role across distinct bladder cancer settings, a central pillar of Tyra’s pipeline.
Against this backdrop, we’ll explore how TYRA-300’s ASCO GU...